TY - JOUR
T1 - Clinical and Genetic Characteristics of 18 Patients from 13 Japanese Families with CRX-associated retinal disorder
T2 - Identification of Genotype-phenotype Association
AU - Japan Eye Genetics Consortium
AU - Fujinami-Yokokawa, Yu
AU - Fujinami, Kaoru
AU - Kuniyoshi, Kazuki
AU - Hayashi, Takaaki
AU - Ueno, Shinji
AU - Mizota, Atsushi
AU - Shinoda, Kei
AU - Arno, Gavin
AU - Pontikos, Nikolas
AU - Yang, Lizhu
AU - Liu, Xiao
AU - Sakuramoto, Hiroyuki
AU - Katagiri, Satoshi
AU - Mizobuchi, Kei
AU - Kominami, Taro
AU - Terasaki, Hiroko
AU - Nakamura, Natsuko
AU - Kameya, Shuhei
AU - Yoshitake, Kazutoshi
AU - Miyake, Yozo
AU - Kurihara, Toshihide
AU - Tsubota, Kazuo
AU - Miyata, Hiroaki
AU - Iwata, Takeshi
AU - Tsunoda, Kazushige
AU - Nishimura, Toshihide
AU - Hayashizaki, Yoshihide
AU - Kondo, Mineo
AU - Shimozawa, Nobuhiro
AU - Horiguchi, Masayuki
AU - Yamamoto, Shuichi
AU - Kuze, Manami
AU - Naoi, Nobuhisa
AU - Machida, Shigeki
AU - Shimada, Yoshiaki
AU - Nakamura, Makoto
AU - Fujikado, Takashi
AU - Hotta, Yoshihiro
AU - Takahashi, Masayo
AU - Mochizuki, Kiyofumi
AU - Murakami, Akira
AU - Kondo, Hiroyuki
AU - Ishida, Susumu
AU - Nakazawa, Mitsuru
AU - Hatase, Tetsuhisa
AU - Matsunaga, Tatsuo
AU - Maeda, Akiko
AU - Noda, Kosuke
AU - Tanikawa, Atsuhiro
AU - Kosaki, Kenjiro
N1 - Funding Information:
Yu Fujinami-Yokokawa is supported by grants from Grant-in-Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology, Japan (18K16943). Kaoru Fujinami is supported by grants from Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H06269), grants from Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16KK01930002), grants from National Hospital Organization Network Research Fund (H30-NHO-Sensory Organs-03), grants from FOUNDATION FIGHTING BLINDNESS ALAN LATIES CAREER DEVELOPMENT PROGRAM (CF-CL-0416-0696-UCL), grants from Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare (201711107A), grants from Japanese agency of medical research and development (AMED; 18ek0109355h0001), and grants from Great Britain Sasakawa Foundation Butterfield Awards. Gavin Arno is supported by a Fight for Sight (UK) Early career investigator award, NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, NIHR-BRC at Great Ormond Street Hospital and UCL Institute of Child Health, and Great Britain Sasakawa Foundation Butterfield Award, UK. Nikolas Pontikos is funded by the NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology. Toshihide Kurihara is supported by Tsubota Laboratory, Inc, Fuji Xerox Co., Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals, Santen Pharmaceutical Co. Ltd, and ROHTO Pharmaceutical Co.,Ltd. Takeshi Iwata is supported by AMED (18ek0109282h0002). Kazushige Tsunoda is supported by AMED, the Ministry of Health, Labor and Welfare, Japan (18ek0109282h0002), Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Japan (H26-26462674), grants from National Hospital Organization Network Research Fund, Japan (H30-NHO-Sensory Organs-03) and Novartis Research Grant (2018). Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Kaoru Fujinami is a paid consultant of Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co., Ltd, and Acucela Inc., Novartis AG., Janssen Pharmaceutica, Sanofi Genzyme, NightstaRx Limited. Kaoru Fujinami reports personal fees from Astellas Pharma Inc, personal fees from Kubota Pharmaceutical Holdings Co., Ltd., personal fees from Acucela Inc., personal fees from NightStar., personal fees from SANTEN Company Limited, personal fees from Foundation Fighting Blindness, personal fees from Foundation Fighting Blindness Clinical Research Institute, personal fees from Japanese Ophthalmology Society, personal fees from Japan Retinitis Pigmentosa Society. Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan is supported by grants from Astellas Pharma Inc (NCT03281005), outside the submitted work. Toshihide Kurihara is supported by Tsubota Laboratory, Inc, Fuji Xerox Co., Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals, Santen Pharmaceutical Co. Ltd, and ROHTO Pharmaceutical Co.,Ltd, outside the submitted work.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Inherited retinal disorder (IRD) is a leading cause of blindness, and CRX is one of a number of genes reported to harbour autosomal dominant (AD) and recessive (AR) causative variants. Eighteen patients from 13 families with CRX-associated retinal disorder (CRX-RD) were identified from 730 Japanese families with IRD. Ophthalmological examinations and phenotype subgroup classification were performed. The median age of onset/latest examination was 45.0/62.5 years (range, 15–77/25–94). The median visual acuity in the right/left eye was 0.52/0.40 (range, −0.08–2.00/−0.18–1.70) logarithm of the minimum angle of resolution (LogMAR) units. There was one family with macular dystrophy, nine with cone-rod dystrophy (CORD), and three with retinitis pigmentosa. In silico analysis of CRX variants was conducted for genotype subgroup classification based on inheritance and the presence of truncating variants. Eight pathogenic CRX variants were identified, including three novel heterozygous variants (p.R43H, p.P145Lfs*42, and p.P197Afs*22). A trend of a genotype-phenotype association was revealed between the phenotype and genotype subgroups. A considerably high proportion of CRX-RD in ADCORD was determined in the Japanese cohort (39.1%), often showing the mild phenotype (CORD) with late-onset disease (sixth decade). Frequently found heterozygous missense variants located within the homeodomain underlie this mild phenotype. This large cohort study delineates the disease spectrum of CRX-RD in the Japanese population.
AB - Inherited retinal disorder (IRD) is a leading cause of blindness, and CRX is one of a number of genes reported to harbour autosomal dominant (AD) and recessive (AR) causative variants. Eighteen patients from 13 families with CRX-associated retinal disorder (CRX-RD) were identified from 730 Japanese families with IRD. Ophthalmological examinations and phenotype subgroup classification were performed. The median age of onset/latest examination was 45.0/62.5 years (range, 15–77/25–94). The median visual acuity in the right/left eye was 0.52/0.40 (range, −0.08–2.00/−0.18–1.70) logarithm of the minimum angle of resolution (LogMAR) units. There was one family with macular dystrophy, nine with cone-rod dystrophy (CORD), and three with retinitis pigmentosa. In silico analysis of CRX variants was conducted for genotype subgroup classification based on inheritance and the presence of truncating variants. Eight pathogenic CRX variants were identified, including three novel heterozygous variants (p.R43H, p.P145Lfs*42, and p.P197Afs*22). A trend of a genotype-phenotype association was revealed between the phenotype and genotype subgroups. A considerably high proportion of CRX-RD in ADCORD was determined in the Japanese cohort (39.1%), often showing the mild phenotype (CORD) with late-onset disease (sixth decade). Frequently found heterozygous missense variants located within the homeodomain underlie this mild phenotype. This large cohort study delineates the disease spectrum of CRX-RD in the Japanese population.
UR - http://www.scopus.com/inward/record.url?scp=85086361389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086361389&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-65737-z
DO - 10.1038/s41598-020-65737-z
M3 - Article
C2 - 32533067
AN - SCOPUS:85086361389
SN - 2045-2322
VL - 10
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 9531
ER -